484 related articles for article (PubMed ID: 21368455)
1. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
3. [Cellular functions of BRCA genes - from basic science to therapeutics].
Miki Y
Gan To Kagaku Ryoho; 2012 Apr; 39(4):498-501. PubMed ID: 22504671
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity.
Kuo ML; Shen SC; Yang CH; Chuang SE; Cheng AL; Huang TS
Oncogene; 1998 Oct; 17(17):2225-34. PubMed ID: 9811453
[TBL] [Abstract][Full Text] [Related]
8. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
9. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
10. [PARP inhibitors: significant progress in cancer therapy].
Dantzer F; Noel G; Schreiber V
Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
[TBL] [Abstract][Full Text] [Related]
11. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
12. [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
Pernin V; Mégnin-Chanet F; Pennaneach V; Fourquet A; Kirova Y; Hall J
Cancer Radiother; 2014 Dec; 18(8):790-8; quiz 799-802. PubMed ID: 25441760
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.
Bryant HE; Helleday T
Biochem Soc Trans; 2004 Dec; 32(Pt 6):959-61. PubMed ID: 15506935
[TBL] [Abstract][Full Text] [Related]
14. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
Nguewa PA; Fuertes MA; Valladares B; Alonso C; Pérez JM
Prog Biophys Mol Biol; 2005 May; 88(1):143-72. PubMed ID: 15561303
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Masutani M; Nakagama H; Sugimura T
Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
[TBL] [Abstract][Full Text] [Related]
17. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.
Mangerich A; Bürkle A
Int J Cancer; 2011 Jan; 128(2):251-65. PubMed ID: 20853319
[TBL] [Abstract][Full Text] [Related]
18. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.
Hay T; Jenkins H; Sansom OJ; Martin NM; Smith GC; Clarke AR
Cancer Res; 2005 Nov; 65(22):10145-8. PubMed ID: 16287996
[TBL] [Abstract][Full Text] [Related]
19. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
Makogon NV; Aleksieieva IM
Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
[TBL] [Abstract][Full Text] [Related]
20. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Jones P; Wilcoxen K; Rowley M; Toniatti C
J Med Chem; 2015 Apr; 58(8):3302-14. PubMed ID: 25761096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
